Verastem, Inc. Files 8-K Report
Ticker: VSTM · Form: 8-K · Filed: Oct 20, 2025 · CIK: 1526119
| Field | Detail |
|---|---|
| Company | Verastem, INC. (VSTM) |
| Form Type | 8-K |
| Filed Date | Oct 20, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, filing
TL;DR
Verastem filed an 8-K, likely with updates. Keep an eye out.
AI Summary
On October 19, 2025, Verastem, Inc. filed an 8-K report. The filing indicates that the company is providing information related to Regulation FD disclosure, other events, and financial statements and exhibits. No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This 8-K filing signals that Verastem, Inc. is making disclosures to the SEC, which could include important updates for investors regarding company events or financial status.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report and the provided excerpt does not contain specific material events or financial data that would indicate immediate risk.
Key Players & Entities
- Verastem, Inc. (company) — Registrant
- October 19, 2025 (date) — Date of earliest event reported
- Needham, MA (location) — Principal Executive Offices
FAQ
What specific event triggered this 8-K filing?
The filing indicates it is for Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits, but the specific triggering event is not detailed in the provided excerpt.
When was the earliest event reported in this filing?
The earliest event reported was on October 19, 2025.
What is Verastem, Inc.'s principal executive office address?
Verastem, Inc.'s principal executive offices are located at 117 Kendrick Street, Suite 500, Needham, MA 02494.
What is Verastem, Inc.'s telephone number?
Verastem, Inc.'s telephone number is (781) 292-4200.
What is Verastem, Inc.'s fiscal year end?
Verastem, Inc.'s fiscal year ends on December 31.
Filing Stats: 887 words · 4 min read · ~3 pages · Grade level 10.2 · Accepted 2025-10-20 06:01:00
Key Financial Figures
- $0.0001 — nge on which registered Common stock, $0.0001 par value per share VSTM The Nasdaq
Filing Documents
- tm2529024d1_8k.htm (8-K) — 28KB
- tm2529024d1_ex99-1.htm (EX-99.1) — 17KB
- 0001104659-25-100537.txt ( ) — 214KB
- vstm-20251019.xsd (EX-101.SCH) — 3KB
- vstm-20251019_lab.xml (EX-101.LAB) — 33KB
- vstm-20251019_pre.xml (EX-101.PRE) — 22KB
- tm2529024d1_8k_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On October 19, 2025, Verastem, Inc. (the "Company") issued a press release announcing updated safety and efficacy data from the GFH375 (known as VS-7375 in the U.S.) ("VS-7375") Phase 1/2 monotherapy study in patients with advanced KRAS G12D mutant pancreatic ductal adenocarcinoma ("PDAC"), a subset of the study population, conducted in China by the Company's partner, GenFleet Therapeutics (Shanghai), Inc. ("GenFleet"). The updated data were featured in a late-breaking abstract for oral presentation by GenFleet at the European Society for Medical Oncology 2025 on October 19, 2025, in Berlin, Germany. A copy of this press release is furnished hereto as Exhibit 99.1 to this Current Report on Form 8-K.
01 Other Events
Item 8.01 Other Events Recent Developments Updated Data from VS-7375 Phase 1/2 Monotherapy Study in Advanced KRAS G12D Mutant PDAC GenFleet reported updated safety and efficacy data specific to patients with advanced KRAS G12D mutant PDAC from the Phase 1/2 monotherapy study in China. The study population includes 66 patients with advanced KRAS G12D mutant PDAC, of which 59 were heavily pre-treated patients with at least two prior lines of anticancer therapy. As of the data cutoff of September 27, 2025, 59 efficacy-evaluable patients had at least one post-treatment tumor assessment and achieved an overall response rate of 40.7% (24/59) (confirmed and unconfirmed) and a disease control rate of 96.7% (57/59), with the majority of patients (91.5%) experiencing a reduction in target lesions when treated with 600 mg of VS-7375 monotherapy per day. Overall Survival ("OS") observed at month four was 92.2%. The median OS was not reached as of the data cutoff, with a median follow-up time of 5.65 months. The median progression-free survival ("PFS") was 5.52 months with a median follow-up time of 5.65 months and a four-month PFS rate of 78.2%. At evaluation, 31 (47%) of patients were still on treatment with the longest duration of treatment eclipsing one year (367 days). The safety profile in PDAC patients was consistent with the previously reported data at recent medical congresses. As of the data cutoff date of August 27, 2025, the most frequent treatment-related adverse events ("TRAEs") occurring in at least 20% of patients were diarrhea, neutrophil count decreased, vomiting, nausea, anemia, white blood cell count decreased, decreased appetite, hypoalbuminemia, platelet count decreased, asthenia, aspartate aminotransferase increased, and alanine transferase increased. Grade 3 TRAEs occurred in 20 patients (30.3%) and a Grade 4 TRAE (neutropenia) occurred in one patient (1.5%). Of the 66 patients in the safety population, four patients (6.1%) had a dose reduction, an
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits Exhibit No. Description 99.1 Press Release, dated October 19, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VERASTEM, INC. Dated: October 20, 2025 By: /s/ Daniel W. Paterson Daniel W. Paterson Chief Executive Officer